Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer.

Moore PA, Shah K, Yang Y, Alderson R, Roberts P, Long V, Liu D, Li JC, Burke S, Ciccarone V, Li H, Fieger CB, Hooley J, Easton A, Licea M, Gorlatov S, King KL, Young P, Adami A, Loo D, Chichili GR, Liu L, Smith DH, Brown JG, Chen FZ, Koenig S, Mather J, Bonvini E, Johnson S.

Mol Cancer Ther. 2018 Aug;17(8):1761-1772. doi: 10.1158/1535-7163.MCT-17-1086. Epub 2018 Jun 4.

2.

FcγRIIb expression in early stage chronic lymphocytic leukemia.

Bosch R, Mora A, Vicente EP, Ferrer G, Jansà S, Damle R, Gorlatov S, Rai K, Montserrat E, Nomdedeu J, Pratcorona M, Blanco L, Saavedra S, Garrido A, Esquirol A, Garcia I, Granell M, Martino R, Delgado J, Sierra J, Chiorazzi N, Moreno C.

Leuk Lymphoma. 2017 Nov;58(11):2642-2648. doi: 10.1080/10428194.2017.1307981. Epub 2017 Apr 4.

3.

MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.

Liu L, Lam CK, Long V, Widjaja L, Yang Y, Li H, Jin L, Burke S, Gorlatov S, Brown J, Alderson R, Lewis MD, Nordstrom JL, Koenig S, Moore PA, Johnson S, Bonvini E.

Clin Cancer Res. 2017 Mar 15;23(6):1506-1518. doi: 10.1158/1078-0432.CCR-16-0666. Epub 2016 Sep 23.

4.

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.

Chichili GR, Huang L, Li H, Burke S, He L, Tang Q, Jin L, Gorlatov S, Ciccarone V, Chen F, Koenig S, Shannon M, Alderson R, Moore PA, Johnson S, Bonvini E.

Sci Transl Med. 2015 May 27;7(289):289ra82. doi: 10.1126/scitranslmed.aaa5693.

PMID:
26019218
5.

Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants.

Lai H, He J, Hurtado J, Stahnke J, Fuchs A, Mehlhop E, Gorlatov S, Loos A, Diamond MS, Chen Q.

Plant Biotechnol J. 2014 Oct;12(8):1098-107. doi: 10.1111/pbi.12217. Epub 2014 Jun 29.

6.

Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus.

He J, Lai H, Engle M, Gorlatov S, Gruber C, Steinkellner H, Diamond MS, Chen Q.

PLoS One. 2014 Mar 27;9(3):e93541. doi: 10.1371/journal.pone.0093541. eCollection 2014.

7.

Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.

Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS.

PLoS Pathog. 2013;9(4):e1003312. doi: 10.1371/journal.ppat.1003312. Epub 2013 Apr 18.

8.

Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.

Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, Son T, Chen Y, Easton AN, Li JC, Rillema JR, Licea M, Fieger C, Liang TW, Mather JP, Koenig S, Stewart SJ, Johnson S, Bonvini E, Moore PA.

Clin Cancer Res. 2012 Jul 15;18(14):3834-45. doi: 10.1158/1078-0432.CCR-12-0715. Epub 2012 May 21.

9.

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.

Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E.

Breast Cancer Res. 2011;13(6):R123. doi: 10.1186/bcr3069. Epub 2011 Nov 30.

10.

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.

Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, Shah K, Jin L, Zhang S, He L, Zhang T, Ciccarone V, Koenig S, Bonvini E, Johnson S.

Blood. 2011 Apr 28;117(17):4542-51. doi: 10.1182/blood-2010-09-306449. Epub 2011 Feb 7.

11.

Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.

Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, Rainey GJ, Ciccarone V, Zhang T, Shah K, Jin L, Ning L, Minor T, Moore PA, Koenig S, Johnson S, Bonvini E.

Arthritis Rheum. 2010 Jul;62(7):1933-43. doi: 10.1002/art.27477.

12.

Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, Yang Y, Jin L, Ciccarone V, Moore PA, Koenig S, Bonvini E.

J Mol Biol. 2010 Jun 11;399(3):436-49. doi: 10.1016/j.jmb.2010.04.001. Epub 2010 Apr 9.

PMID:
20382161
13.

Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice.

Lai H, Engle M, Fuchs A, Keller T, Johnson S, Gorlatov S, Diamond MS, Chen Q.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2419-24. doi: 10.1073/pnas.0914503107. Epub 2010 Feb 1.

14.

Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, Fremont DH, Diamond MS, Pierson TC.

Cell Host Microbe. 2009 Oct 22;6(4):381-91. doi: 10.1016/j.chom.2009.09.003.

15.

Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Koenig S, Bonvini E.

Adv Enzyme Regul. 2008;48:152-64. doi: 10.1016/j.advenzreg.2007.11.011. Epub 2007 Dec 3. No abstract available.

PMID:
18177741
16.

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.

Cancer Res. 2007 Sep 15;67(18):8882-90. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692. Vijh, Sujata [added].

17.

Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.

Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S.

Immunology. 2007 Jul;121(3):392-404. Epub 2007 Mar 26.

18.

CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.

Rankin CT, Veri MC, Gorlatov S, Tuaillon N, Burke S, Huang L, Inzunza HD, Li H, Thomas S, Johnson S, Stavenhagen J, Koenig S, Bonvini E.

Blood. 2006 Oct 1;108(7):2384-91. Epub 2006 Jun 6.

19.

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.

Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS.

Nat Med. 2005 May;11(5):522-30. Epub 2005 Apr 24.

20.

Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin-binding site.

Yakovlev S, Gorlatov S, Ingham K, Medved L.

Biochemistry. 2003 Jul 1;42(25):7709-16.

PMID:
12820880
22.
24.
26.

In vivo effect of GroESL on the folding of glutamate racemase of Escherichia coli.

Ashiuchi M, Yoshimura T, Kitamura T, Kawata Y, Nagai J, Gorlatov S, Esaki N, Soda K.

J Biochem. 1995 Mar;117(3):495-8.

27.

Supplemental Content

Loading ...
Support Center